Clinical Trials
30 trialsRT4
The Lymphoma Academic Research Organisation
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Ruijin Hospital
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Peking University People's Hospital
Caris Biorepository Research Protocol
Caris Science, Inc.
EURHOLY
Assistance Publique - Hôpitaux de Paris
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
RenJi Hospital
MRD-ATLAS
Shanghai Zhongshan Hospital
NeckTAR-IN
Centre Jean Perrin
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
University Hospital, Montpellier
Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer
Shanghai Zhongshan Hospital
CR1STAL
Second Xiangya Hospital of Central South University
NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL
The Children's Hospital of Zhejiang University School of Medicine
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
Institute of Hematology & Blood Diseases Hospital, China
R0 Resection Rate Between CSP, cEMR and hEMR for 1-2 cm Colorectal SSLs
National Taiwan University Hospital
SURPASS
Sun Yat-sen University
Neuro3DUS
University of Ulm
MARTINI
University of Leicester
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
Institute of Hematology & Blood Diseases Hospital, China
ADVANCE-II
Mendus
LAL1913
Gruppo Italiano Malattie EMatologiche dell'Adulto
Validation of a Score That Predicts Residual Disease in Incidental Gallbladder Cancer
Hospital Universitari de Bellvitge
VMRDO
Centre Hospitalier Universitaire de Besancon
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Nanfang Hospital, Southern Medical University
Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy
Yonsei University
Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer
Università degli Studi dell'Insubria
OVAMAR
University Hospital, Clermont-Ferrand
TESTIMAR
University Hospital, Clermont-Ferrand
MRD-1
Novartis